Table 1 Baseline characteristics of the patients
Characteristic* | Metformin (n = 39) | Placebo (n = 42) | p value |
|---|---|---|---|
Age | 71 (56–82) | 73 (49–86) | 0.22 |
Weight (kg) | 95.5 (62.7–157.0) | 91.6 (71.8–126.1) | 0.24 |
Waist Circumference (cm) | 110 (81.5–185) | 109 (92–185) | 0.60 |
BMI (kg/m2) | 30.3 (22.2–52.5) | 29.8 (23.7–40.4) | 0.40 |
Mean SBP (mmHg) | 145 (108–179) | 142.5 (103–173.5) | 0.92 |
HbA1C (%) | 5.6 (5.1–6.4) | 5.6 (4.9–6.4) | 0.95 |
Smoking Pack-Year-History | 15 (0–107.5) | 20 (0–75) | 0.56 |
Marital Status—no. (%) married | 31 (79.5) | 37 (88.1) | 0.29 |
ECOG | 0 (0–1) | 0 (0–1) | 0.59 |
Total IPSS | 11 (0–31) | 10 (0–22) | 0.86 |
Gleason Score | 9 (7–9) | 8 (7–9) | 0.44 |
% Biopsy Cores Positive | 7 (2–14) | 7 (2–12) | 0.62 |
Clinical T-Stage—no. (%) T1 T2 T3 | 13 (33) 16 (41) 10 (26) | 13 (31) 16 (38) 13 (31) | 0.87 |
Pelvic Nodal Irradiation—no. (%) | 30 (71) | 33 (79) | 0.82 |
Prostate Boost Type—no. (%) | |||
Standard Fractionation (76/38 to 78/39) | 24 (62) | 24 (57) | 0.90 |
Hypofractionated (60/20, 70/28, 72.8/28) | 11 (28) | 13 (31) | |
Interstitial Brachytherapy Boost | 4 (10) | 5 (12) |